Taiyen Biotech Co. Ltd.(TW:1737)
NT$29.900.00 (-0.17%)
TW:1737
Taiyen Biotech Co. Ltd. financials statements
NT$29.90
At close:0.00 (-0.17%)
Taiyen Biotech Co. Ltd. (1737) Ratios
Taiyen Biotech Co. Ltd. Ratios
TW:1737's free cash flow for Q2 2026 was NT$61.77M. For the 2026 fiscal year, TW:1737's free cash flow was decreased by NT$-38.03M and operating cash flow was NT$99.80M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.87 | 2.51 | 2.75 | 3.34 | 2.60 |
| Quick Ratio | 2.48 | 2.15 | 2.39 | 2.90 | 2.30 |
| Cash Ratio | 1.41 | 1.33 | 1.31 | 1.65 | 1.32 |
| Solvency Ratio | 0.45 | 0.34 | 0.28 | 0.40 | 0.30 |
| Operating Cash Flow Ratio | 0.49 | 0.57 | 0.41 | 0.63 | 0.46 |
| Short-Term Operating Cash Flow Coverage | 2.50 | 2.43 | 2.14 | 3.59 | 1.48 |
| Net Current Asset Value | NT$ 1.31B | NT$ 1.21B | NT$ 1.26B | NT$ 1.54B | NT$ 1.44B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.04 | 0.04 | 0.03 | 0.06 |
| Debt-to-Equity Ratio | 0.03 | 0.05 | 0.05 | 0.04 | 0.08 |
| Debt-to-Capital Ratio | 0.03 | 0.04 | 0.05 | 0.04 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Financial Leverage Ratio | 1.21 | 1.26 | 1.28 | 1.26 | 1.33 |
| Debt Service Coverage Ratio | 3.22 | 1.95 | 1.94 | 3.23 | 1.51 |
| Interest Coverage Ratio | 140.95 | 67.97 | 93.36 | 118.31 | 86.82 |
| Debt to Market Cap | 0.03 | 0.04 | 0.04 | 0.04 | 0.07 |
| Interest Debt Per Share | 1.15 | 1.59 | 1.60 | 1.36 | 2.56 |
| Net Debt to EBITDA | -1.56 | -1.88 | -2.13 | -1.97 | -1.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 40.60% | 40.79% | 35.49% | 35.33% | 33.53% |
| EBIT Margin | 14.34% | 13.57% | 9.75% | 12.32% | 12.92% |
| EBITDA Margin | 21.77% | 20.32% | 15.56% | 17.71% | 17.55% |
| Operating Profit Margin | 14.40% | 13.30% | 9.17% | 14.81% | 12.60% |
| Pretax Profit Margin | 14.93% | 13.37% | 9.65% | 14.68% | 12.45% |
| Net Profit Margin | 12.09% | 11.47% | 8.81% | 11.81% | 9.60% |
| Continuous Operations Profit Margin | 11.90% | 9.80% | 6.37% | 11.83% | 10.06% |
| Net Income Per EBT | 80.95% | 85.80% | 91.27% | 80.42% | 77.12% |
| EBT Per EBIT | 103.74% | 100.52% | 105.26% | 99.15% | 98.85% |
| Return on Assets (ROA) | 4.84% | 4.43% | 3.61% | 5.20% | 4.64% |
| Return on Equity (ROE) | 5.87% | 5.58% | 4.63% | 6.54% | 6.18% |
| Return on Capital Employed (ROCE) | 6.52% | 5.97% | 4.33% | 7.34% | 7.20% |
| Return on Invested Capital (ROIC) | 5.06% | 4.21% | 2.78% | 5.78% | 5.50% |
| Return on Tangible Assets | 4.85% | 4.44% | 3.61% | 5.20% | 4.65% |
| Earnings Yield | 6.41% | 5.72% | 4.39% | 6.57% | 5.92% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.20 | 6.50 | 5.14 | 5.29 | 5.41 |
| Payables Turnover | 8.48 | 6.12 | 7.65 | 8.78 | 7.34 |
| Inventory Turnover | 5.21 | 4.49 | 5.57 | 5.74 | 6.89 |
| Fixed Asset Turnover | 0.80 | 0.80 | 0.87 | 0.97 | 1.15 |
| Asset Turnover | 0.40 | 0.39 | 0.41 | 0.44 | 0.48 |
| Working Capital Turnover Ratio | 1.86 | 1.76 | 1.67 | 1.70 | 1.91 |
| Cash Conversion Cycle | 85.86 | 77.90 | 88.82 | 91.05 | 70.77 |
| Days of Sales Outstanding | 58.89 | 56.17 | 71.02 | 68.99 | 67.52 |
| Days of Inventory Outstanding | 70.00 | 81.35 | 65.52 | 63.62 | 52.96 |
| Days of Payables Outstanding | 43.03 | 59.62 | 47.72 | 41.57 | 49.70 |
| Operating Cycle | 128.90 | 137.52 | 136.53 | 132.62 | 120.48 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.41 | 3.30 | 2.27 | 2.90 | 3.00 |
| Free Cash Flow Per Share | 0.88 | 1.76 | 0.55 | 1.67 | 1.05 |
| Dividend Paid and CapEx Coverage Ratio | 0.85 | 1.21 | 0.71 | 1.06 | 0.91 |
| Capital Expenditure Coverage Ratio | 1.58 | 2.15 | 1.33 | 2.35 | 1.54 |
| Operating Cash Flow Coverage Ratio | 2.12 | 2.12 | 1.43 | 2.16 | 1.18 |
| Operating Cash Flow to Sales Ratio | 0.14 | 0.20 | 0.13 | 0.16 | 0.15 |
| Free Cash Flow Yield | 2.78% | 5.43% | 1.60% | 5.15% | 3.15% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 15.85 | 17.45 | 22.80 | 15.23 | 16.85 |
| Price-to-Sales (P/S) Ratio | 1.89 | 2.00 | 2.01 | 1.80 | 1.62 |
| Price-to-Book (P/B) Ratio | 0.92 | 0.97 | 1.06 | 1.00 | 1.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 35.94 | 18.41 | 62.60 | 19.43 | 31.73 |
| Price-to-Operating Cash Flow Ratio | 13.17 | 9.83 | 15.07 | 11.18 | 11.07 |
| Price-to-Earnings Growth (PEG) Ratio | 2.11 | 0.73 | -0.77 | 1.88 | 2.20 |
| Enterprise Value Multiple | 7.10 | 7.98 | 10.78 | 8.17 | 7.54 |
| Enterprise Value | 5.11B | 5.25B | 5.72B | 5.23B | 5.42B |
| EV to EBITDA | 7.10 | 7.98 | 10.78 | 8.17 | 7.54 |
| EV to Sales | 1.55 | 1.62 | 1.68 | 1.45 | 1.32 |
| EV to Free Cash Flow | 29.46 | 14.89 | 52.29 | 15.65 | 25.90 |
| EV to Operating Cash Flow | 10.79 | 7.95 | 12.59 | 9.01 | 9.03 |
| Tangible Book Value Per Share | 34.56 | 33.28 | 32.67 | 33.28 | 32.52 |
| Shareholders’ Equity Per Share | 34.62 | 33.32 | 32.41 | 32.61 | 31.81 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.20 | 0.27 | 0.34 | 0.19 | 0.19 |
| Revenue Per Share | 16.80 | 16.19 | 17.02 | 18.07 | 20.48 |
| Net Income Per Share | 2.03 | 1.86 | 1.50 | 2.13 | 1.97 |
| Tax Burden | 0.81 | 0.86 | 0.91 | 0.80 | 0.77 |
| Interest Burden | 1.04 | 0.99 | 0.99 | 1.19 | 0.96 |
| Research & Development to Revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
| SG&A to Revenue | 0.25 | 0.26 | 0.24 | 0.21 | 0.19 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.18 | 1.78 | 1.51 | 1.36 | 1.18 |
Currency in TWD
